MUM1

A step ahead toward the understanding of lymphoma histogenesis

G. Gaidano, A. Carbone

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

In recent times, the field of B cell lymphoma histogenesis has progressed rapidly due to the increasing availability of histogenetic markers. Genotypic markers of B cell histogenesis are represented by mutations of IgV and BCL-6 genes, which are somatically acquired at the time of B cell transit through the germinal center (GC). Phenotypic markers are represented by BCL-6 and CD138/syndecan-1 protein expression and allow the distinction between GC and post-GC B cells. On this basis, lymphomas may be histogenetically distinguished into: (1) lymphomas devoid of somatic IgV and BCL-6 hypermutation, which derive from pre-germinal center B cells; (2) lymphomas associated with somatic IgV and/or BCL-6 hypermutation and BCL-6 expression, which closely reflect germinal center B cells; and (3) lymphomas associated with somatic IgV and/or BCL-6 hypermutation, as well as CD138/syndecan-1 positivity, representing lymphomas of post-germinal center B cells. In the March issue of Leukemia, Tsuboi et al report on the expression pattern of MUM1 in normal lymphoid tissues and in lymphoma. Because expression of MUM1 protein appears to be strictly regulated during lymphoid differentiation, and because expression of the molecule is retained upon neoplastic transformation, MUM1 may be added to the panel of phenotypic markers of B cell lymphoma histogenesis. In particular, MUM1 may provide a marker for the identification of transition from BCL-6 positivity (GC B cells) to CD138 expression (immunoblasts and plasma cells). These studies are of potential clinical value, since in some B cell malignancies, histogenesis may influence prognosis.

Original languageEnglish
Pages (from-to)563-566
Number of pages4
JournalLeukemia
Volume14
Issue number4
Publication statusPublished - 2000

Fingerprint

Germinal Center
Lymphoma
B-Lymphocytes
Syndecan-1
B-Cell Lymphoma
Lymphoid Tissue
Plasma Cells
Leukemia
Proteins
Mutation
Genes
Neoplasms

Keywords

  • Histogenesis
  • Lymphoma
  • MUM-1/ICSAT/IRF-4/PIP
  • Pathogenesis

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Gaidano, G., & Carbone, A. (2000). MUM1: A step ahead toward the understanding of lymphoma histogenesis. Leukemia, 14(4), 563-566.

MUM1 : A step ahead toward the understanding of lymphoma histogenesis. / Gaidano, G.; Carbone, A.

In: Leukemia, Vol. 14, No. 4, 2000, p. 563-566.

Research output: Contribution to journalArticle

Gaidano, G & Carbone, A 2000, 'MUM1: A step ahead toward the understanding of lymphoma histogenesis', Leukemia, vol. 14, no. 4, pp. 563-566.
Gaidano, G. ; Carbone, A. / MUM1 : A step ahead toward the understanding of lymphoma histogenesis. In: Leukemia. 2000 ; Vol. 14, No. 4. pp. 563-566.
@article{28b9d1ed34d24a6cb1d5682f436c3faa,
title = "MUM1: A step ahead toward the understanding of lymphoma histogenesis",
abstract = "In recent times, the field of B cell lymphoma histogenesis has progressed rapidly due to the increasing availability of histogenetic markers. Genotypic markers of B cell histogenesis are represented by mutations of IgV and BCL-6 genes, which are somatically acquired at the time of B cell transit through the germinal center (GC). Phenotypic markers are represented by BCL-6 and CD138/syndecan-1 protein expression and allow the distinction between GC and post-GC B cells. On this basis, lymphomas may be histogenetically distinguished into: (1) lymphomas devoid of somatic IgV and BCL-6 hypermutation, which derive from pre-germinal center B cells; (2) lymphomas associated with somatic IgV and/or BCL-6 hypermutation and BCL-6 expression, which closely reflect germinal center B cells; and (3) lymphomas associated with somatic IgV and/or BCL-6 hypermutation, as well as CD138/syndecan-1 positivity, representing lymphomas of post-germinal center B cells. In the March issue of Leukemia, Tsuboi et al report on the expression pattern of MUM1 in normal lymphoid tissues and in lymphoma. Because expression of MUM1 protein appears to be strictly regulated during lymphoid differentiation, and because expression of the molecule is retained upon neoplastic transformation, MUM1 may be added to the panel of phenotypic markers of B cell lymphoma histogenesis. In particular, MUM1 may provide a marker for the identification of transition from BCL-6 positivity (GC B cells) to CD138 expression (immunoblasts and plasma cells). These studies are of potential clinical value, since in some B cell malignancies, histogenesis may influence prognosis.",
keywords = "Histogenesis, Lymphoma, MUM-1/ICSAT/IRF-4/PIP, Pathogenesis",
author = "G. Gaidano and A. Carbone",
year = "2000",
language = "English",
volume = "14",
pages = "563--566",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - MUM1

T2 - A step ahead toward the understanding of lymphoma histogenesis

AU - Gaidano, G.

AU - Carbone, A.

PY - 2000

Y1 - 2000

N2 - In recent times, the field of B cell lymphoma histogenesis has progressed rapidly due to the increasing availability of histogenetic markers. Genotypic markers of B cell histogenesis are represented by mutations of IgV and BCL-6 genes, which are somatically acquired at the time of B cell transit through the germinal center (GC). Phenotypic markers are represented by BCL-6 and CD138/syndecan-1 protein expression and allow the distinction between GC and post-GC B cells. On this basis, lymphomas may be histogenetically distinguished into: (1) lymphomas devoid of somatic IgV and BCL-6 hypermutation, which derive from pre-germinal center B cells; (2) lymphomas associated with somatic IgV and/or BCL-6 hypermutation and BCL-6 expression, which closely reflect germinal center B cells; and (3) lymphomas associated with somatic IgV and/or BCL-6 hypermutation, as well as CD138/syndecan-1 positivity, representing lymphomas of post-germinal center B cells. In the March issue of Leukemia, Tsuboi et al report on the expression pattern of MUM1 in normal lymphoid tissues and in lymphoma. Because expression of MUM1 protein appears to be strictly regulated during lymphoid differentiation, and because expression of the molecule is retained upon neoplastic transformation, MUM1 may be added to the panel of phenotypic markers of B cell lymphoma histogenesis. In particular, MUM1 may provide a marker for the identification of transition from BCL-6 positivity (GC B cells) to CD138 expression (immunoblasts and plasma cells). These studies are of potential clinical value, since in some B cell malignancies, histogenesis may influence prognosis.

AB - In recent times, the field of B cell lymphoma histogenesis has progressed rapidly due to the increasing availability of histogenetic markers. Genotypic markers of B cell histogenesis are represented by mutations of IgV and BCL-6 genes, which are somatically acquired at the time of B cell transit through the germinal center (GC). Phenotypic markers are represented by BCL-6 and CD138/syndecan-1 protein expression and allow the distinction between GC and post-GC B cells. On this basis, lymphomas may be histogenetically distinguished into: (1) lymphomas devoid of somatic IgV and BCL-6 hypermutation, which derive from pre-germinal center B cells; (2) lymphomas associated with somatic IgV and/or BCL-6 hypermutation and BCL-6 expression, which closely reflect germinal center B cells; and (3) lymphomas associated with somatic IgV and/or BCL-6 hypermutation, as well as CD138/syndecan-1 positivity, representing lymphomas of post-germinal center B cells. In the March issue of Leukemia, Tsuboi et al report on the expression pattern of MUM1 in normal lymphoid tissues and in lymphoma. Because expression of MUM1 protein appears to be strictly regulated during lymphoid differentiation, and because expression of the molecule is retained upon neoplastic transformation, MUM1 may be added to the panel of phenotypic markers of B cell lymphoma histogenesis. In particular, MUM1 may provide a marker for the identification of transition from BCL-6 positivity (GC B cells) to CD138 expression (immunoblasts and plasma cells). These studies are of potential clinical value, since in some B cell malignancies, histogenesis may influence prognosis.

KW - Histogenesis

KW - Lymphoma

KW - MUM-1/ICSAT/IRF-4/PIP

KW - Pathogenesis

UR - http://www.scopus.com/inward/record.url?scp=0034076767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034076767&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 563

EP - 566

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 4

ER -